[Iatrogenic Cushing's syndrome, diabetes mellitus and secondary adrenal failure in a human immunodeficiency virus patient treated with ritonavir boosted atazanavir and fluticasone].
Ritonavir and atazanavir (ATZ) are protease inhibitors (PI) that inhibit the P450 3A4 cytochrome. They are used together to boost ATZ levels and reduce pill burden in human immunodeficiency virus infection, but association with medications metabolized by this cytochrome can cause serious adverse effects. Several cases of Cushing's syndrome have been reported when patients received inhaled therapy with fluticasone for asthma, sometimes complicated by secondary adrenal failure after stopping fluticasone. We report a case of Cushing's syndrome associated with onset of diabetes mellitus in a patient treated with boosted PI (ATZ and ritonavir) for HIV 2 (CD4360/ml). Asthma was treated with inhaled fluticasone 1500mug/day for several months that was stopped at admission. A few days later, typical secondary adrenal failure developed and was confirmed by dosage of cortisol and ACTH, both low. Hydrocortisone replacement treatment resulted in rapid improvement of symptoms. Diabetes was initially treated with insulin then sulfonyluraes, but repeated hypoglycemias lead to diet alone. Physicians should be aware of the potential danger of the association of "boosted" IP and some kind of inhaled corticotherapy.
Collet-Gaudillat
C
C
Service d'endocrinologie-diabétologie, hôpital André-Mignot, centre hospitalier de Versailles, 177, rue de Versailles, 78157, Le-Chesnay cedex, France. ccollet@ch-versailles.fr
Roussin-Bretagne
S
S
Desforges-Bullet
V
V
Petit-Aubert
G
G
Doll
J
J
Beressi
J -P
J-
D000280:Administration, Inhalation; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000730:Androstadienes / Q000009:adverse effects*; D001786:Blood Glucose / Q000378:metabolism; D001993:Bronchodilator Agents / Q000009:adverse effects; D003404:Creatinine / Q000378:metabolism; D003480:Cushing Syndrome / Q000150:complications* / Q000188:drug therapy; D048909:Diabetes Complications / Q000188:drug therapy; D003927:Diet, Diabetic; D000068298:Fluticasone; D006442:Glycated Hemoglobin / Q000378:metabolism; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects; D015498:HIV-2; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019438:Ritonavir / Q000009:adverse effects*; D013974:Thyroxine / Q000097:blood
D000324:Adrenocorticotropic Hormone; D000730:Androstadienes; D001786:Blood Glucose; D001993:Bronchodilator Agents; D003404:Creatinine; D000068298:Fluticasone; D006442:Glycated Hemoglobin; D017320:HIV Protease Inhibitors; D006854:Hydrocortisone; D019438:Ritonavir; D013974:Thyroxine